COVID-19-associated hepatic injury differential diagnosis: Difference between revisions
Jump to navigation
Jump to search
TayyabaAli (talk | contribs) No edit summary |
TayyabaAli (talk | contribs) |
||
Line 28: | Line 28: | ||
|- | |- | ||
| rowspan="6" style="background:#4479BA; color: #FFFFFF" |Acute viral hepatitis | | rowspan="6" style="background:#4479BA; color: #FFFFFF" |Acute viral hepatitis | ||
| style="padding: 5px 5px; background: #DCDCDC;" align="center" |[[Hepatitis A]] | | style="padding: 5px 5px; background: #DCDCDC;" align="center" |[[Hepatitis A]]<ref name="pmid20068336">{{cite journal| author=Jeong SH, Lee HS| title=Hepatitis A: clinical manifestations and management. | journal=Intervirology | year= 2010 | volume= 53 | issue= 1 | pages= 15-9 | pmid=20068336 | doi=10.1159/000252779 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=20068336 }} </ref><ref name="pmid16418523">{{cite journal| author=Nainan OV, Xia G, Vaughan G, Margolis HS| title=Diagnosis of hepatitis a virus infection: a molecular approach. | journal=Clin Microbiol Rev | year= 2006 | volume= 19 | issue= 1 | pages= 63-79 | pmid=16418523 | doi=10.1128/CMR.19.1.63-79.2006 | pmc=1360271 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=16418523 }} </ref> | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | +++ | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | +++ | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | ++ | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | ++ | ||
Line 42: | Line 42: | ||
* [[Fever]] usually present | * [[Fever]] usually present | ||
|- | |- | ||
| style="padding: 5px 5px; background: #DCDCDC;" align="center" |[[Hepatitis B]] | | style="padding: 5px 5px; background: #DCDCDC;" align="center" |[[Hepatitis B]]<ref name="pmid29877316">{{cite journal| author=Yuen MF, Chen DS, Dusheiko GM, Janssen HLA, Lau DTY, Locarnini SA | display-authors=etal| title=Hepatitis B virus infection. | journal=Nat Rev Dis Primers | year= 2018 | volume= 4 | issue= | pages= 18035 | pmid=29877316 | doi=10.1038/nrdp.2018.35 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=29877316 }} </ref> | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | +++ | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | +++ | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | ++ | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | ++ | ||
Line 56: | Line 56: | ||
* [[Fever]] usually present | * [[Fever]] usually present | ||
|- | |- | ||
| style="padding: 5px 5px; background: #DCDCDC;" align="center" |[[Hepatitis C]] | | style="padding: 5px 5px; background: #DCDCDC;" align="center" |[[Hepatitis C]]<ref name="pmid25609256">{{cite journal| author=Mukherjee R, Burns A, Rodden D, Chang F, Chaum M, Garcia N | display-authors=etal| title=Diagnosis and Management of Hepatitis C Virus Infection. | journal=J Lab Autom | year= 2015 | volume= 20 | issue= 5 | pages= 519-38 | pmid=25609256 | doi=10.1177/2211068214563794 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=25609256 }} </ref> | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | +++ | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | +++ | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |<nowiki>++</nowiki> | | style="padding: 5px 5px; background: #F5F5F5;" align="center" |<nowiki>++</nowiki> | ||
Line 71: | Line 71: | ||
* [[Fever]] usually present | * [[Fever]] usually present | ||
|- | |- | ||
| style="padding: 5px 5px; background: #DCDCDC;" align="center" |[[Hepatitis E]] | | style="padding: 5px 5px; background: #DCDCDC;" align="center" |[[Hepatitis E]]<ref name="pmid24396139">{{cite journal| author=Kamar N, Dalton HR, Abravanel F, Izopet J| title=Hepatitis E virus infection. | journal=Clin Microbiol Rev | year= 2014 | volume= 27 | issue= 1 | pages= 116-38 | pmid=24396139 | doi=10.1128/CMR.00057-13 | pmc=3910910 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=24396139 }} </ref> | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |<nowiki>++</nowiki> | | style="padding: 5px 5px; background: #F5F5F5;" align="center" |<nowiki>++</nowiki> | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |<nowiki>++</nowiki> | | style="padding: 5px 5px; background: #F5F5F5;" align="center" |<nowiki>++</nowiki> | ||
Line 159: | Line 159: | ||
* May cause both cholestatic or hepatocellular injury | * May cause both cholestatic or hepatocellular injury | ||
|} | |} | ||
== References == | == References == | ||
{{reflist|2}} | {{reflist|2}} |
Revision as of 10:21, 21 July 2020
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Tayyaba Ali, M.D.[2]
Overview
COVID-19-associated hepatic Injury must be differentiated from other conditions that cause elevation of liver enzymes.
Differential Diagnosis
COVID-19-associated hepatic Injury must be differentiated from other conditions that cause elevation of liver enzymes.
Disease | Clinical manifestations | Laboratory findings | Additional findings | |||||||
---|---|---|---|---|---|---|---|---|---|---|
Symptoms | Signs | Transaminitis (elevated AST and ALT) | Viral markers | Autoimmune markers | ||||||
Nausea & vomiting | Abdominal pain | Arthralgia | Jaundice | Hepatomegaly | ||||||
Acute viral hepatitis | Hepatitis A[1][2] | +++ | ++ | + | +++ | + | +++ | HAV Ab | --- |
|
Hepatitis B[3] | +++ | ++ | ++ | +++ | + | +++ | HBs Ag, HBc Ab, HBe Ag | --- |
| |
Hepatitis C[4] | +++ | ++ | ++ | +++ | + | +++ | HCV Ab | --- |
| |
Hepatitis E[5] | ++ | ++ | +/- | ++ | + | +++ | HEV Ab | --- |
| |
CMV hepatitis | +/- | ++ | - | + | + | ++ | CMV-specific immunoglobulin (Ig)M antibody | -- |
| |
EBV hepatitis | +/- | ++ | - | +/- | + | ++ | Heterophile antibody test, monospot test | -- |
| |
Autoimmune hepatitis | - | + | +/- | ++ | + | +++ | --- | ANA, ASMA, anti SLA/LP, ANCA, ALKM-1 antibodies |
| |
Alcoholic hepatitis | +/- | + | - | + | - | AST>ALT | --- | --- |
| |
Drug induced hepatitis | +/- | + | - | + | + | ++ | --- | --- |
| |
COVID-19-associated hepatic Injury | + | + | - | - | + | ++ | IgG/IgM Antibodies[6] | --- |
|
References
- ↑ Jeong SH, Lee HS (2010). "Hepatitis A: clinical manifestations and management". Intervirology. 53 (1): 15–9. doi:10.1159/000252779. PMID 20068336.
- ↑ Nainan OV, Xia G, Vaughan G, Margolis HS (2006). "Diagnosis of hepatitis a virus infection: a molecular approach". Clin Microbiol Rev. 19 (1): 63–79. doi:10.1128/CMR.19.1.63-79.2006. PMC 1360271. PMID 16418523.
- ↑ Yuen MF, Chen DS, Dusheiko GM, Janssen HLA, Lau DTY, Locarnini SA; et al. (2018). "Hepatitis B virus infection". Nat Rev Dis Primers. 4: 18035. doi:10.1038/nrdp.2018.35. PMID 29877316.
- ↑ Mukherjee R, Burns A, Rodden D, Chang F, Chaum M, Garcia N; et al. (2015). "Diagnosis and Management of Hepatitis C Virus Infection". J Lab Autom. 20 (5): 519–38. doi:10.1177/2211068214563794. PMID 25609256.
- ↑ Kamar N, Dalton HR, Abravanel F, Izopet J (2014). "Hepatitis E virus infection". Clin Microbiol Rev. 27 (1): 116–38. doi:10.1128/CMR.00057-13. PMC 3910910. PMID 24396139.
- ↑ Lippi G, Simundic AM, Plebani M (2020). "Potential preanalytical and analytical vulnerabilities in the laboratory diagnosis of coronavirus disease 2019 (COVID-19)". Clin Chem Lab Med. 58 (7): 1070–1076. doi:10.1515/cclm-2020-0285. PMID 32172228 Check
|pmid=
value (help).